UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Laboratory biomarkers of Multiple Sclerosis (MS)

Clinical biochemistry, 2022-01, Vol.99, p.1-8

2022

Volltextzugriff (PDF)

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis

PloS one, 2012-02, Vol.7 (2), p.e31784-e31784

2012

Volltextzugriff (PDF)

Experimental laboratory biomarkers in multiple sclerosis

Wiener medizinische Wochenschrift, 2022-11, Vol.172 (15-16), p.346-358

2022

Volltextzugriff (PDF)

The Use of Kappa Free Light Chains to Diagnose Multiple Sclerosis

Medicina (Kaunas, Lithuania), 2022-10, Vol.58 (11), p.1512

2022

Volltextzugriff (PDF)

Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria

Journal of neurology, 2024-06, Vol.271 (6), p.3142-3152

2024

Volltextzugriff (PDF)

Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry

Journal of neurology, 2019-11, Vol.266 (11), p.2672-2677

2019

Volltextzugriff (PDF)

Sex impacts treatment decisions in multiple sclerosis

Journal of neurology, 2024-06, Vol.271 (6), p.3256-3267

2024

Volltextzugriff (PDF)

Tumefactive MS lesions under fingolimod: a case report and literature review

Neurology, 2013-11, Vol.81 (19), p.1654-1658

2013

Volltextzugriff (PDF)

The increasing incidence and prevalence of female multiple sclerosis—A critical analysis of potential environmental factors

Autoimmunity reviews, 2011-06, Vol.10 (8), p.495-502

2011

Volltextzugriff (PDF)

Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria

Journal of neurology, 2023-06, Vol.270 (6), p.3103-3111

2023

Volltextzugriff (PDF)

Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

Journal of neurology, 2021-11, Vol.268 (11), p.4303-4310

2021

Volltextzugriff (PDF)

Real‐life use of oral disease‐modifying treatments in Austria

Acta neurologica Scandinavica, 2019-07, Vol.140 (1), p.32-39

2019

Volltextzugriff (PDF)

Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukencephalopathy with an excellent outcome

Clinical & experimental neuroimmunology, 2015-05, Vol.6 (2), p.172-174

2015

Volltextzugriff (PDF)

Oral therapies for treatment of relapsing–remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method

Journal of neurology, 2020-07, Vol.267 (7), p.2090-2100

2020

Volltextzugriff (PDF)

Multiple sclerosis in the elderly: a retrospective cohort study

Journal of neurology, 2024-02, Vol.271 (2), p.674-687

2024

Volltextzugriff (PDF)

Management of autonomic dysfunction in severe tetanus: the importance of deep analgosedation

Intensive care medicine, 2007-02, Vol.33 (2), p.380-381

2007

Volltextzugriff (PDF)

Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction

Fluids and barriers of the CNS, 2020-02, Vol.17 (1), p.7-7, Article 7

2020

Volltextzugriff (PDF)

Do elevated autoantibodies in patients with multiple sclerosis matter?

Acta neurologica Scandinavica, 2019-03, Vol.139 (3), p.238-246

2019

Volltextzugriff (PDF)

Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people

PloS one, 2013-11, Vol.8 (11), p.e79649-e79649

2013

Volltextzugriff (PDF)

The impact of interferon-β treatment on the blood–brain barrier

Drug discovery today, 2006-08, Vol.11 (15), p.755-762

2006

Volltextzugriff (PDF)

Treatment strategies for vasculitis that affects the nervous system

Drug discovery today, 2013-09, Vol.18 (17-18), p.818-835

2013

Volltextzugriff (PDF)

Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome

Journal of neurology, 2017-04, Vol.264 (4), p.799-801

2017

Volltextzugriff (PDF)

Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?

Clinical chemistry and laboratory medicine, 2013-11, Vol.51 (11), p.2073-2086

2013

Volltextzugriff (PDF)

Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy

Biomedicines, 2021-10, Vol.9 (11), p.1584

2021

Volltextzugriff (PDF)

1 – 25 von 272

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(175)
Mit Volltextzugriff
(233)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(173)
Deutsch
(106)
Italienisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Laboratory biomarkers of Multiple Sclerosis (MS)

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis

Experimental laboratory biomarkers in multiple sclerosis

The Use of Kappa Free Light Chains to Diagnose Multiple Sclerosis

Early intensive versus escalation treatment in patients with relapsing–remitting multiple sclerosis in Austria

Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry

Sex impacts treatment decisions in multiple sclerosis

Tumefactive MS lesions under fingolimod: a case report and literature review

The increasing incidence and prevalence of female multiple sclerosis—A critical analysis of potential environmental factors

Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing–remitting multiple sclerosis in Austria

Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

Real‐life use of oral disease‐modifying treatments in Austria

Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukencephalopathy with an excellent outcome

Oral therapies for treatment of relapsing–remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method

Multiple sclerosis in the elderly: a retrospective cohort study

Management of autonomic dysfunction in severe tetanus: the importance of deep analgosedation

Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German–Austrian retrospective multicenter study in patients with a clinically isolated syndrome

Do elevated autoantibodies in patients with multiple sclerosis matter?

Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people

The impact of interferon-β treatment on the blood–brain barrier

Treatment strategies for vasculitis that affects the nervous system

Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome

Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?

Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy

Suchergebnisse filtern